Integrative Clinical, Hormonal and Molecular Data associate with Invasiveness in Acromegaly: REMAH Study

CONCLUSIONS: A specific combination of clinical/analytical/molecular variables was found to be associated with tumor invasiveness and growth capacity in GHomas. Pre-treatment with first-line drugs for acromegaly did not significantly modify the expression of the most relevant biomarkers in our association model. These findings provide valuable insights for risk stratification and personalized management of GHomas.PMID:38701338 | DOI:10.1093/ejendo/lvae045

Source: European Journal of Endocrinology - May 3, 2024 Category: Endocrinology Authors: Miguel Sampedro-Nu ñez Aura Dulcinea Herrera-Mart ínez Alejandro Ib áñez-Costa Esther Rivero-Cort és Eva Venegas Mercedes Robledo Rebeca Mart ínez-Hernández Araceli Garc ía-Martínez Joan Gil Mireia Jord à Judith L ópez-Fernández Inmaculada Gav Source Type: research